Geographic variations of human papilloma virus infection and their possible impact on the effectiveness of the vaccination programme

Oncology Reports

Volumn 20, Issue 1, 2008, Pages 141-145

  Mammas, Ioannis N ^a   Vageli, Dimitra ^b   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

Geographic variations; Greece; Human papilloma virus; Vaccination programme

Indexed keywords

B RAF KINASE; K RAS PROTEIN; WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER GRADING; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GEOGRAPHIC DISTRIBUTION; GREECE; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; POINT MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS DETECTION; VIRUS INFECTION; VIRUS TYPING; WART VIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; ONCOGENE RAS; VIROLOGY;

ADULT; FEMALE; GENES, RAS; GREECE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 49849092035     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.20.1.141     Document Type: Article

References (33)

1. Sanclemente G and Gill DK: Human papillomavirus molecular biology and pathogenesis. J Eur Acad Dermatol Venereol 16: 231-240, 2002.
2. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
3. Peto J, Gilham C, Deacon J, et al: Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 91: 942-953, 2004.
4. Munoz N, Bosch FX, de Sanjose S, et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003.
5. Munoz N, Bosch FX, Castellsague X, et al: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111: 278-285, 2004.
6. Clifford GM, Smith JS, Plummer M, Munoz N and Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88: 63-73, 2003.
7. Clifford GM, Rana RK, Franceschi S, Smith J, Gough G and Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14: 1157-1164, 2005.
8. Clifford GM, Smith JS, Aguardo T and Franceschi S: Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89: 101-105, 2003.
9. Villa LL, Coste RL, Petta CA, et al: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6: 271-278, 2005.
10. Harper DM, Franco EL, Wheeler CM, et al: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247-1255, 2006.
11. Galloway DA: Papillomavirus vaccines in clinical trials. Lancet Infect Dis 3: 469-475, 2003.
12. Noutsou A, Koffa M, Ergazaki M, Siafakas N and Spandidos DA: Detection of human papilloma virus (HPV) and K-ras mutations in human lung carcinomas. Int J Oncol 8: 1089-1093, 1996.
13. Dokianakis DN, Sourvinos G, Sakkas S, Athanasiadou E and Spandidos D: Detection of HPV and ras gene mutations in cervical smears from female genital lesions. Oncol Rep 5: 1195-1198, 1998.
14. Mammas IN, Zafiropoulos A, Sifakis S, Sourvinos G and Spandidos DA: Human Papilloma Virus (HPV) typing in relation to ras oncogene mRNA expression in HPV-associated human squamous cervical neoplasia. Int J Biol Markers 20: 257-263, 2006.
15. Symvoulakis EK, Zavarinos A, Panutsopoulos D, Zoras O, Papalambros E, Sigala F and Spandidos DA: Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. Int J Biol Markers 22: 12-18, 2007.
16. Hildesheim A and Wang SS: Host and viral genetics and risk of cervical cancer: a review. Virus Res 89: 229-240, 2002.
17. Chong H, Vikis HG and Guan KL: Mechanisms of regulating the Raf kinase family. Cell Signal 15: 463-469, 2003.
18. Macaluso M, Russo G, Cinti C, Bazan V, Gebbia N and Russo A: Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol 192: 125-130, 2002.
19. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
20. Kiaris H and Spandidos DA: Mutations of ras genes in human tumours. Int J Oncol 7: 413-421, 1995.
21. Mammas IN, Zafiropoulos A and Spandidos DA: Involvement of ras genes in female genital tract cancer (Review). Int J Oncol 26: 1241-1255, 2005.
22. Salvesen HB, Kumar R, Stefansson I, et al: Low frequency of BRAF and CDKN2A mutations in endometrial cancer. Int J Cancer 115: 930-934, 2005.
23. Chan SY, Delius H, Halpern L and Bernard HU: Analysis of genomic sequencies of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol 69: 3074-3083, 1995.
24. Koffa M, Koumantakis E, Ergazki M, Malamou-Mitsi V and Spandidos DA: Detection of ras mutations and HPV in lesions of the human female reproductive tract. Int J Oncol 5: 189-195, 1994.
25. Agorastos T, Bontis J, Lambropoulos A, et al: Epidemiology of human papillomavirus infection in Greek asymptomatic women. Eur J Cancer Prev 4: 159-167, 1995.
26. Labropoulou V, Diakomanolis E, Dailianas A, Kalpaktsoglou K, Balamotis A and Mavromara P: Type-specific prevalence of genital human papillomaviruses in benign, premalignant and malignant biopsies in patients from Greece. Sex Transm Dis 24: 467-474, 1997.
27. Lambropoulos A, Dimitrakopoulos J, Frangoulides, et al: Incidence of human papillomavirus 6, 11, 16, 18 and 33 in normal oral mucosa of a Greek population. Eur J Oral Sci 105: 294-297, 1997.
28. Dokianakis DN, Papaefthimiou M, Tsiveleka A and Spandidos DA: High prevalence of HPV-18 in correlation with ras gene mutations and clinicopathological parameters in cervical cancer studied from stained cytological smears. Oncol Rep 6: 1327-1331, 1999.
29. Aggelopoulou EP, Skarlos D, Papadimitriou C, Kittas C and Troungos C: Human papilloma virus DNA detection in oral lesions in the Greek population. Anticancer Res 19: 1391-1395, 1999.
30. Prokopakis P, Sourvinos G, Koumantaki Y, Koumantakis E and Spandidos DA: K-ras mutations and HPV infection in cervitis and intraepithelial neoplasias of the cervix. Oncol Rep 9: 129-133, 2002.
31. Roussaki-Schulze AV, Kouskoukis C, Rammos C, et al: Identification of human papillomavirus DNA in melanoma biopsy specimens of Greek population. Int J Clin Pharmacol Res 25: 145-150, 2005.
32. Lyronis ID, Baritaki S, Bizakis I, Tsardi M and Spandidos DA: Evaluation of the prevalence of human papillomavirus and Epstein-Barr virus in esophageal squamous cell carcinomas. Int J Biol Markers 20: 5-10, 2005.
33. Mammas IN, Sourvinos G, Michael C and Spandidos DA: Human papilloma virus in hyperplastic tonsillar and adenoid tissues in children. Pediatr Infect Dis J 25: 1158-1162, 2006.